We are live on ! Find out more
MNPR icon

Monopar Therapeutics
MNPR

82 hedge funds and large institutions have $342M invested in Monopar Therapeutics in 2026 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 33 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 18

82% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 11

11% more funds holding

Funds holding: 74 → 82 (+8)

10.61% more ownership

Funds ownership: 82.71% → 93.32% (+11%)

5% less capital invested

Capital invested by funds: $361M → $342M (-$19.3M)

Holders
82
Holders Change
+8
Holders Change %
+10.81%
% of All Funds
1.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
33
Reduced
18
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Sio Capital Management
New York
+$10.5M
2
DM
Deerfield Management
New York
+$9.25M
3
PCH
Polar Capital Holdings
United Kingdom
+$7.3M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$6.31M
5
VPC
Vestal Point Capital
New York
+$3.95M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$20M
2
DTC
Deep Track Capital
Connecticut
-$6.23M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.12M
4
Millennium Management
Millennium Management
New York
-$1.43M
5
Citigroup
Citigroup
New York
-$822K
Name Holding Trade Value Shares
Change 		Change in
Stake
VPM
26
Vanguard Portfolio Management
Pennsylvania
$2.52M +$2.78M +45,987 New
SCM
27
Silverarc Capital Management
Massachusetts
$2.38M +$2.63M +43,488 New
Neuberger Berman Group
28
Neuberger Berman Group
New York
$2.32M +$597K +9,887 +30%
UBS Group
29
UBS Group
Switzerland
$2.16M +$2.13M +35,186 +828%
Goldman Sachs
30
Goldman Sachs
New York
$1.9M +$1.47M +24,349 +235%
DCM
31
Driehaus Capital Management
Illinois
$1.82M -$33.8K -559 -2%
Northern Trust
32
Northern Trust
Illinois
$1.75M +$83K +1,374 +5%
Deutsche Bank
33
Deutsche Bank
Germany
$1.58M +$1.54M +25,449 +754%
VFT
34
Vanguard Fiduciary Trust
Pennsylvania
$1.56M +$1.72M +28,447 New
Barclays
35
Barclays
United Kingdom
$1.37M +$283K +4,690 +23%
JF
36
Jump Financial
Illinois
$1.25M +$1.38M +22,808 New
Morgan Stanley
37
Morgan Stanley
New York
$1.22M -$281K -4,655 -17%
Squarepoint
38
Squarepoint
New York
$1.19M +$679K +11,233 +107%
Russell Investments Group
39
Russell Investments Group
United Kingdom
$781K +$840K +13,908 +4,079%
Charles Schwab
40
Charles Schwab
California
$688K -$104K -1,727 -12%
Two Sigma Investments
41
Two Sigma Investments
New York
$535K +$288K +4,776 +96%
SEI Investments
42
SEI Investments
Pennsylvania
$415K +$39.6K +656 +9%
WG
43
Winton Group
United Kingdom
$374K +$413K +6,829 New
Ameriprise
44
Ameriprise
Minnesota
$374K +$412K +6,819 New
EI
45
EAM Investors
California
$341K -$311K -5,148 -45%
Creative Planning
46
Creative Planning
Kansas
$328K +$362K +5,987 New
TD Asset Management
47
TD Asset Management
Ontario, Canada
$322K +$169K +2,800 +91%
GL
48
Gerber LLC
Ohio
$307K – – –
N
49
Nuveen
North Carolina
$304K – – –
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$271K -$2.66K -44 -0.9%
1
2
3 4

MNPR Hedge Fund Activity: Q1 2026 in Review

82 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q1 2026, worth a combined $342M — down 5.3% from $361M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new MNPR positions and 11 closed out — a net gain of 9 holders — while 33 added to existing stakes and 18 trimmed.

The largest buyer was Sio Capital Management, opening a new position worth an estimated $10.5M. The largest seller was Adage Capital Partners, cutting an estimated $20M.

  • 82 institutional investors held Monopar Therapeutics (MNPR) as of Q1 2026, up from 74 in Q4 2025.
  • Funds reported $342M of Monopar Therapeutics stock for Q1 2026, down 5.3% quarter-over-quarter.
  • 20 funds opened new Monopar Therapeutics positions in Q1 2026 and 11 closed out, a net change of +9 holders.
  • The largest Monopar Therapeutics buyer in Q1 2026 was Sio Capital Management, an estimated $10.5M added.
  • The largest Monopar Therapeutics seller in Q1 2026 was Adage Capital Partners, an estimated $20M sold.

Based on aggregated 13F filings for Q1 2026.